Pharma Industry
Pharma Industry 03/02/2012
Merck & Co enjoys healthy quarter but expects flat sales in 2012
Turnover from the HIV drug Isentress (raltegravir) reached $387 million, up 24%.
Pharma Industry 02/02/2012
Vertex reports fourth quarter and full year 2011 financial results
Successful launch of INCIVEK (telaprevir) for hepatitis C and recent approval of KALYDECO (ivacaftor) for cystic fibrosis position Vertex for continued growth, earnings and cashflow.
Pharma Industry 02/02/2012
Gilead Sciences announces fourth quarter and full year 2011 financial results
Fourth guarter product sales of $2.13 billion, up 11% year over year; Full year 2011 product sales of $8.10 billion, up 10% over 2010; Full year 2011 non-GAAP EPS of $3.86, up 5% over 2010; Full year 2011 operating cash flows of $3.64 billion.
Pharma Industry 02/02/2012
Indian pharma's outlook stable for 2012, says Fitch
Fitch Ratings says its outlook on India's pharmaceutical sector for 2012 remains stable, with earnings prospects remaining positive because of the growing global demand for generics and opportunities provided by patent expiries in developed markets.
Pharma Industry 01/02/2012
Market Research projects HIV/AIDS testing market growth at 5.2% CAGR through 2014
New report "Global HIV/AIDS Testing Market 2010-2014".
Pharma Industry 01/02/2012
Roche places bets on new products for 2012 growth
Roche’s 2011 earnings may have experienced a 4% drop but the company is remaining optimistic about growth in the new year as new products flood onto the market.
Pharma Industry 29/01/2012
New products provide solid quarter for BMS
Sales of the Sustiva (efavirenz) franchise rise 14% to $412 million, and Reyataz (atazanavir) is up 11% to $416 million.
Pharma Industry 26/01/2012
Gilead tops table for antivirals
With combined sales from the top HIV treatment on the market, Atripla, and several other drugs, Gilead Sciences leads the antiviral market, closely followed by Bristol-Myers Squibb, Roche and Merck & Co.
Pharma Industry 24/01/2012
Vertex vows to fight on with Alios drugs in high-stakes hepatitis C race
“There isn’t one magic pill that will solve the problem. It’s clear the HCV space will evolve into different combination treatments for different patients. It’s not yet clear what the best combination is going to be. What you want is to have the component parts in your company so you can put them together.”
Pharma Industry 24/01/2012
BioLineRx signs exclusive license agreement for BL-8020, an oral treatment for hepatitis C
BL-8020 acts via a unique mechanism of action, which differs from the mechanism of currently used anti-HCV agents.
Pharma Industry 20/01/2012
Pharma M&A "surged back" in 2011
Last year, the value of mergers and acquisitions (M&A) in the pharmaceutical industry surged to $224 billion, the highest level recorded since 2007.
Pharma Industry 20/01/2012
Achillion shares fall on concerns over hep C drug's future
Achillion Pharmaceuticals' shares fell 12 percent, shedding some of their recent gains amid concerns raised by an investment website on the future of the company's key hepatitis C drug.
Pharma Industry 17/01/2012
Generics market to boom as blockbusters go off-patent
The global generics market is likely to witness strong growth driven by the patent expiry of several major blockbuster drugs worth $150 billion between 2010 and 2017.
Pharma Industry 16/01/2012
Bristol-Myers raised offer 30% to beat competitor for Inhibitex
Bristol-Myers Squibb Co. increased its bid for Inhibitex Inc. and its experimental hepatitis C drug twice in five days, raising its offer 30 percent to top an unnamed competitor.
Pharma Industry 16/01/2012
Pfizer tests a concept that could modernize drug studies
For the pharmaceutical industry, it’s another part of the business that cries out for change: the complex and costly human studies involved in developing new medicines.
Pharma Industry 13/01/2012
Battling borderless bugs
Western and emerging-market drug firms are invading each other’s turf.
Pharma Industry 12/01/2012
Follow the money: Where pharma is investing
A new report underscores how drugmakers are seeking low-cost venues for their most labor-intensive activities.
Pharma Industry 12/01/2012
A lack of progress? Blame it on the FDA
An overwhelming majority of CEOs blame the FDA for slowing the growth of their companies.
Pharma Industry 11/01/2012
GeoVax Labs' CEO update letter to shareholders
"During 2011, GeoVax achieved steady progress in developing our HIV/AIDS vaccines and continued to lay a solid foundation for continued clinical and corporate success. While we are pleased with our results, our goal for 2012 is to achieve even greater and more timely progress."
Pharma Industry 10/01/2012
Reluctant placebo supplies undermining independent trials
Without a legal obligation to provide placebos to match their marketed drugs, the pharmaceutical industry has de-facto control over drug trials.
More...
